-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GqTXqZdiQZmbOLUGpl8TqCUnVphgqAZrLDMyn9oLszMN3DCOMqdUrfQ9aKopLu2g z3uHhiEQtYepoBtIakCYPQ== 0001012870-97-001909.txt : 19971007 0001012870-97-001909.hdr.sgml : 19971007 ACCESSION NUMBER: 0001012870-97-001909 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19970930 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19971006 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALZA CORP CENTRAL INDEX KEY: 0000004310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770142070 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-06247 FILM NUMBER: 97690917 BUSINESS ADDRESS: STREET 1: 950 PAGE MILL RD STREET 2: PO BOX 10950 CITY: PALO ALTO STATE: CA ZIP: 94303-0802 BUSINESS PHONE: 4154945000 MAIL ADDRESS: STREET 1: 950 PAGE MILL RD STREET 2: PO BOX 10950 CITY: PALO ALTO STATE: CA ZIP: 94303 8-K 1 FORM 8-K FOR PERIOD SEPTEMBER 30, 1997 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SEPTEMBER 30, 1997 Date of Report (Date of earliest event reported) ALZA CORPORATION (Exact Name of Registrant as Specified in its Charter) _____________________________________________________ DELAWARE 1-6247 77-0142070 (State or other (Commission File Number) (I.R.S. Employer Jurisdiction of Identification No.) Incorporation) ________________________________________ 950 Page Mill Road P.O. BOX 10950 PALO ALTO, CALIFORNIA 94303-0802 (Address of Principal Executive Offices)(Zip Code) Registrant's telephone number, including area code: (650) 494-5000 _____________________________________________________ ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS. On September 30, 1997, ALZA Corporation ("ALZA") completed a special distribution of shares of Crescendo Pharmaceuticals Corporation ("Crescendo") Class A Common Stock to the holders of ALZA Common Stock and ALZA's outstanding convertible subordinated debentures. Holders of record on September 18, 1997 (the "Record Date") received one Crescendo share for every 20 shares of ALZA Common Stock owned on the Record Date, one Crescendo share for every 36 shares of ALZA Common Stock into which the holder's 5% convertible subordinated debentures were convertible on the Record Date, and one Crescendo share for every 37 shares of ALZA Common Stock into which the holder's 5 1/4% zero coupon convertible subordinated debentures were convertible on the Record Date, with cash distributed in lieu of fractional shares. Prior to the distribution, ALZA contributed $300 million in cash to Crescendo. The Crescendo shares are quoted on the Nasdaq National Market under the symbol "CNDO." Under agreements between ALZA and Crescendo, ALZA will undertake the development of products for Crescendo. ALZA has the option to license each Crescendo product and an option to purchase all the Crescendo Class A Common Stock at a price set according to a predetermined formula. Approximately 4,965,470 shares of Crescendo were distributed. The distribution is expected to be a taxable dividend to the holders of ALZA Common Stock and taxable interest to holders of the debentures. The press release announcing the completion of the distribution is attached as Exhibit 99.1 hereto and is incorporated by reference herein. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits Exhibit 99.1 - Press Release issued by ALZA Corporation on September 30, 1997. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ALZA CORPORATION /s/Peter D. Staple ------------------ By: Peter D. Staple Senior Vice President and General Counsel Date: October 2, 1997 EXHIBIT INDEX Exhibit 99.1 - Press Release issued by ALZA Corporation on September 30, 1997. EX-99.1 2 PRESS RELEASE EXHIBIT 99.1 ALZA Distributes Shares of Crescendo Pharmaceuticals Corporation September 30, 1997 9:01 AM EDT PALO ALTO, Calif., Sept. 30 -- ALZA Corporation (NYSE: AZA) today will complete the previously announced special distribution of shares of Crescendo Pharmaceuticals Corporation Class A common stock to the holders of ALZA common stock and ALZA's outstanding convertible subordinated debentures. Holders of record as of September 18, 1997 will receive one Crescendo share for every 20 shares of ALZA common stock owned, one Crescendo share for every 36 shares of ALZA common stock into which the holder's 5% convertible subordinated debentures are convertible, and one Crescendo share for every 37 shares of ALZA common stock into which the holder's 5 1/4% zero coupon convertible subordinated debentures are convertible. Cash will be distributed in lieu of fractional shares. Crescendo was recently formed by ALZA for the purpose of selecting and developing new human pharmaceutical products for commercialization, most likely through licensing to ALZA. Prior to the distribution, ALZA contributed $300 million in cash to Crescendo. Under agreements between ALZA and Crescendo, ALZA will undertake the development of products for Crescendo. ALZA has the option to license each Crescendo product, and an option to purchase all the Crescendo Class A common stock at a price set according to a predetermined formula. The total number of Crescendo shares being distributed is approximately 4,965,471. Crescendo shares will be quoted on the Nasdaq National Market under the symbol "CNDO." The distribution is expected to be a taxable dividend to the holders of ALZA common stock, and taxable interest to holders of the debentures. ALZA Corporation is a leader in the development and commercialization of innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies. -----END PRIVACY-ENHANCED MESSAGE-----